 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This indicator may be signaling that AGIO's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Agios Pharmaceuticals (AGIO, $22.2) entered Downtrend as Momentum indicator drops below 0 level on Nov 29, 2023

40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence;One Study Patient Achieved Hemoglobin Response Endpoint Safety Profile Consistent with Data Reported in Healthy...

Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals (AGIO, $22.26) entered Downtrend as Momentum indicator drops below 0 level on Nov 17, 2023

Agios Pharmaceuticals GAAP EPS of -$1.64 beats by $0.06, revenue of $7.4M misses by $0.13M...

Agios Pharmaceuticals GAAP EPS of -$1.64 beats by $0.06, revenue of $7.4M misses by $0.13M

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Agios Pharmaceuticals reports Q3 EPS ($1.64), consensus ($1.70)

We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't...

Even after rising 5.6% this past week, Agios Pharmaceuticals (NASDAQ:AGIO) shareholders are still down 71% over the past five years

First Patient Dosed in Phase 3 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease Completed Enrollment in Phase 3 ACTIVATE-KidsT Pediatric Study of Mitapivat in PK...

Agios Reports Business Highlights and Third Quarter 2023 Financial Results

This is a Bullish indicator signaling AGIO's price could rise from here. Traders may explore going long the stock or buying call options...

Agios Pharmaceuticals (AGIO, $21.3) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 1, 2023

Agios Pharmaceuticals Inc (AGIO) announces Q3 2023 financial results and business highlightsRelated Stocks: AGIO...

Agios Pharmaceuticals Inc (AGIO) Reports Q3 2023 Earnings, Reveals 10% Increase in U.S. Net Revenue

Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support...

Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Watchers	2,473
52-Wk Low	$19.80
52-Wk High	$31.87

Market Cap	$1.59B
Volume (M)	249,995.00
52-Wk High	$31.87
52-Wk Low	$19.80

AGIO Agios Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community